Kornimate/medical-research-clean huggingface dataset:
neurological soft signs in neurodegenerative dementias

Conditions: Alzheimer Disease; Dementia With Lewy Bodies; Frontotemporal Dementia; Corticobasal Degeneration

Summary: the goal of this observational study is to investigate the prevalence of neurological soft signs (nss) in various categories of dementia patients compared to matched controls. the main questions it aims to answer are: * does the prevalence of nss significantly differ among patients with neurodegenerative dementias compared to controls? * are nss associated with neuropsychiatric alterations in dementia patients? * do nss correlate with cognitive screening tools? * do nss increase over time in patients with neurodegenerative dementias? participants will undergo assessments including: * evaluation of nss using the heidelberg scale * neuropsychiatric assessments * cognitive screening using the mini-mental state examination (mmse) and frontal assessment battery (fab) researchers will compare dementia groups (alzheimer's disease, frontotemporal dementia, corticobasal syndrome and lewy body dementia) to controls to determine differences in nss prevalence. additionally, associations between nss and neuropsychiatric symptoms, as well as cognitive performance, will be explored.


Eligibility criteria:
inclusion criteria: * diagnosis of probable alzheimer's disease (ad), frontotemporal dementia (ftd), corticobasal syndrome (cbs), or probable lewy body dementia (lbd) according to established clinical criteria. * mmse score greater than 10. * age and gender-matched controls without a history of neurological or psychiatric conditions. exclusion criteria: * mixed dementia or vascular etiology. * history of neurological or psychiatric conditions predating the dementia diagnosis. * substance or alcohol abuse history. * known comorbidities affecting neurological or psychiatric function. * mmse score less than or equal to 10. * inability to provide informed consent.
candesartan in peripheral neuropathy

Conditions: Peripheral Neuropathy

Summary: background: chemotherapy induced peripheral neuropathy (cipn) is often painful, and is caused by neurotoxic chemotherapy including vincristine. it is a cause of significant impairment in quality of life in patients surviving to a solid cancer or malignant lymphoma. the only recognized prevention is based on pre-existing neuropathy and early detection of neuropathic signs and symptoms in individuals subjected to neurotoxic chemotherapy, justifying sometimes a change in the therapeutic strategy when other molecules are available. it seems obvious that to identify early markers of cipn and to develop preventive therapeutic strategies, are priorities for improving patients' quality of life and enable them to follow optimal treatment. purpose: to describe in patients treated for non-hodgkin's type b malignant lymphoma with multidrug therapy containing vincristine, the impact of candesartan on the occurrence of neuropathy measured by the variation of tnsc (total neuropathy score clinical version, evaluating clinical signs of neuropathy)


Eligibility criteria:
inclusion criteria: * patients aged 18 years and over and to be treated with vincristine for non-hodgkin b lymphoma (first line treatment) * all the patients have to be treated with the same chemotherapy protocol (chop with or without rituximab) to avoid confounding factors * normal renal function as measured by ckd-epi \> 30 mmol / min / 1.73 m2 * serum potassium \< 5.5 mmol / l * systolic arterial pressure \> 100 mm hg (lying and standing position) * affiliated with a social security * for women of childbearing age: under "highly effective" contraception and negative pregnancy test at inclusion. highly effective contraception: * combined hormonal contraceptive (containing estrogen and progesterone) (oral, intravaginal, or transdermal) or only progesterone (oral, injectable or implantable), exclusion criteria: * patients with pre-existing neuropathy, chronic ethylism, hiv infection, etc. * patients under guardianship or unable for another reason to give informed consent. * intolerance to sartans * intolerance to excipients : galactose , lactose. * patients already treated with ace inhibitors, arbs or/and diuretics sparing
"safety, tolerability and pharmacokinetics of mp-376 administered for 14 days to stable pediatric (cf) patients"

Conditions: Cystic Fibrosis

Summary: patients with cystic fibrosis (cf) suffer from chronic infections of the lower respiratory tract that can be caused by one or multiple bacteria, including pseudomonas aeruginosa, which has been particularly problematic to eradicate and been implicated as the major cause of morbidity and mortality in cf patients. aerosol delivery of antibiotics directly to the lung increases the local concentrations of antibiotic at the site of infection resulting in improved antimicrobial effects compared to systemic administration. bacterial resistance to current aerosol antibiotic treatments indicate a need for improved therapies to treat cf patients with pulmonary infections caused by multi-drug resistant pseudomonas aeruginosa and other bacteria. high concentrations of mp-376 delivered directly to the lung are projected to have antimicrobial effects on even the most resistant organisms. mp-376 is a novel formulation of the fluoroquinolone levofloxacin that has been optimized for aerosol delivery using the pari electronic eflow® nebulizer. preclinical and early clinical studies in adults show that aerosol doses of mp-376 appear to be safe and well tolerated, and exert an antimicrobial effect when administered once or twice daily. high concentrations of levofloxacin in the lung delivered using mp-376 are expected to be active against cf pathogens such as p. aeruginosa and s. aureus, including those resistant to aminoglycosides (such as tobi®) and other inhaled antimicrobial agents. inhaled mp-376 can be delivered rapidly and efficiently using the pari eflow® nebulizer system. this phase 1 study is being performed to obtain safety, tolerability and pk data in children ages 6-16 in order to determine if mp-376 is safe, prior to enrolling children of these ages in the planned pivotal phase 3 studies.

a phase 1b, multi-center, open label study to evaluate the safety, tolerability and pharmacokinetics of mp-376 inhalation solution given daily for 14 days to stable pediatric cystic fibrosis patients. study acquired from horizon in 2024.

Eligibility criteria:
inclusion criteria (selected): * 6 to 16 years of age (inclusive) at visit 1 * weight is greater than or equal to 14 kilograms (kg) * confirmed diagnosis of cystic fibrosis * patients are able to elicit an fev1 \>/= 25% of predicted value (wang criteria) * clinically stable with no changes in health status within the last 14 days * able to reproducibly undergo spirometry testing exclusion criteria (selected): * use of any nebulized or systemic antibiotics within 7 days prior to baseline * history of intolerance or hypersensitivity to fluoroquinolones or intolerance with aerosol medications including bronchodilators * crcl \ /= 3 x uln at screening or evidence of severe liver disease
epigallocatechin gallate (egcg) to improve cognitive performance in foetal alcohol syndrome (fas) children

Conditions: Fetal Alcohol Syndrome (FAS)

Summary: the flavonoid epigallocatechin gallate (egcg) is a modulator of neuronal plasticity useful in other neurodevelopmental diseases. a recent study showed that egcg is a promising tool for cognitive and health related quality of life improvement in down's syndrome. the objective is to determine the efficacy of egcg as a therapeutic candidate for the improvement of cognitive performance in fas patients. pre and post study, non randomized, controlled and without placebo, to evaluate the efficacy of egcg. it is a pilot study in a cohort of 40 fas children, between 7 ans 14 years old. an oral dose of 9 mg/kg/day will be administered during 1 year, with 6 control visits until 6 months after finishing the treatment.

background 1% of children present a prenatal alcohol exposure related disorder. prevalence of consumption increases every year. in a previous study in barcelona, 45.5% of ethanol positive meconiums were detected, as a biomarker of maternal consumption of alcohol during pregnancy. the most serious clinical picture including facial, mental and cognitive disorders is foetal alcohol syndrome (fas). spain is the second country in adoptions from east europe, where the consumption of alcohol during pregnancy is most important. the only prevention of fas is avoiding consumption of alcohol during pregnancy and there is no treatment for its deleterious effects on neurodevelopment. the flavonoid epigallocatechin gallate (egcg) is a modulator of neuronal plasticity useful in other neurodevelopmental diseases. a recent study showed that egcg is a promising tool for cognitive and health related quality of life improvement in down's syndrome. objective to determine the efficacy of egcg as a therapeutic candidate for the improvement of cognitive performance in fas patients. methodology pre and post study, non randomized, controlled and without placebo, to evaluate the efficacy of egcg. it is a pilot study in a cohort of 40 fas children, between 7 ans 14 years old. an oral dose of 9 mg/kg/day will be administered during 1 year, with 6 control visits until 6 months after finishing the treatment. instrumentalization 1. cognitive and neuropsychologic diagnostic scales of fas 2. determination of values of oxidative stress 3. determination of control biomarkers of the treatment

Eligibility criteria:
inclusion criteria: 1. fas diagnosed children between 7 and 14 y.o. 2. included in a previous cohort (almar) 3. informed consent by parents exclusion criteria: 1. refuse of parents to participate 2. unfulfillment of inclusion criteria 3. any condition in children preventing from fas diagnostics tests application

Keywords: fetal alcohol syndrome prenatal exposure biomarkers oxidative stress epigallocatechin gallate
minimal erythema dose of uv-b in normal population of taiwan

Conditions: Human Volunteers

Summary: there is no previous study on the minimal erythema dose of uvb irradiation in chinese people. we will investigate the correlation of skin phototype, constitutive skin color, facultative skin color and minimal erythema dose in taiwanese.

the skin phototype will be obtained from a structuralized questionaire. the constitutive skin color and facultative skin color will be obtained by chromameter. the minimal erythema dose will be obtained by physician's assessment.

Eligibility criteria:
inclusion criteria: 10-65 years old normal healthy volunteers exclusion criteria: age under 10 years old or older than 65 years old people with a past history of photo-sensitivity people who had been treated with phototherapy

Keywords: minimal erythema dose uvb normal
effects of cervical spine manipulation

Conditions: Cervical Pain

Summary: to determine the immediate effects of cervical spine manipulation on pressure pain sensitivity on upper trapezius trigger point. it was a randomized control trial including 66 patients at physiotherapy opd of railway rehabilitation center from august 2019 to december 2019, railway general hospital pakistan and max rehab and decompression center max health hospital g8 islamabad. the subjects were randomly divided into two groups (group control and experimental) by free envelope method.

to determine the immediate effects of cervical spine manipulation on pressure pain sensitivity on upper trapezius trigger point and neck ranges of motion. a randomized control trial of 66 patients was conducted from august 2019 to december 2019 at physiotherapy opd of railway rehabilitation center, railway general hospital pakistan and max rehab and decompression center maxhealth hospital g8 islamabad. the subjects were randomly divided into two groups (group control and experimental) by free envelope method. control was treated with manual pressure release followed by stretching while in experimental received cervical spine manipulation (chin hold) kaltenborn followed by stretching. structural questionnaire was used for pre and post assessment. outcomes were measured by algometry and inclinometer before and after the application of respective techniques. the data was analyzed at baseline and immediately after the intervention on ibm spss-21.

Eligibility criteria:
inclusion criteria: * 1.presence mtrps in upper trapezius * limited side bending and rotation * both gender * age between 25 to 45 exclusion criteria: * malignancy, infection, trauma, bone deformities. * acute disc protrusion * positive vbi * positive sharp purser test * history of whiplash injury
adrenal insufficiency in septic shock

Conditions: Septic Shock; Acute Adrenal Insufficiency

Summary: randomized controlled trial evaluating the duration of steroid replacement therapy in patients with adrenal insufficiency and septic shock. patients will be randomized to receive either hydrocortisone 50 mg iv every six hours for seven days (control) or hydrocortisone 50 mg iv every six hours until 24 hours after achievement of hemodynamic stability (map \> 65 mm hg off of vasopressors).


Eligibility criteria:
inclusion criteria: * patients who are 18 years of age or older * patients who sign informed consent or are represented by a legally authorized representative to provide consent on behalf of the patient * patients with septic shock meeting the accm/sccm consensus conference definitions for septic shock exclusion criteria: * patients with documented allergic or anaphylactic reactions to corticosteroids * patients who have received steroid therapy within 6 months of presentation * patients who have received steroids during their hospital admission, with the exception of a single dose of dexamethasone * patients who have received etomidate in the preceding 12 hours * patients who have had a prior adrenalectomy or a known history of adrenal disease (documented adrenal insufficiency or cushing syndrome). * documented human immunodeficiency virus (hiv) infection * pregnancy * allergies to adrenocorticotropic hormone (acth) or corticosteroids * administration of additional medications which may suppress the hypothalamic-pituitary axis: * ketoconazole * aminoglutethimide * mitotane * megestrol acetate * suramin

Keywords: septic shock acute adrenal insufficiency
immunogenicity study of antibody persistence and booster effect of dtap-hb-prp~t combined vaccine or tritanrix-hepb/hib™

Conditions: Diphtheria; Tetanus; Pertussis; Hepatitis B; Haemophilus Influenzae Type b

Summary: the present trial is a follow-up of al203 study (nct00343889). primary objectives: to describe the antibody persistence at 15 to 18 months of age and the booster effect of a dose of dtap-hb-prp\~t or tritanrix-hepb/hib™ (given concomitantly with oral polio vaccine \[opv\]). secondary objective: to describe the safety profile of a booster dose of dtap-hb-prp\~t or tritanrix-hepb/hib™ when administered concomitantly with opv in each vaccine group.

study participants will receive a booster vaccination of dtap-hb-prp\~t or tritanrix-hepb/hib™ either concomitantly with oral polio vaccine (opv) following the completion of a three dose primary series with dtap-hep b-prp-t combined vaccine or tritanrix hepb/hib™, both given concomitantly with opv. participants will receive a booster dose of the vaccine they had received in the primary series, and a concomitant dose of opv study al203 (nct00343889).

Eligibility criteria:
inclusion criteria: * toddler aged 15 to 18 months of age on the day of inclusion (range: 456 days to 578 days of age inclusive) * participated in the al203 study and completed the three-dose primary series with either dtap-hb-prp\~t or tritanrix-hepb/hib™, and opv, at 6, 10 and 14 weeks of age * informed consent form signed by one parent or legal representative if appropriate (independent witness mandatory if parent is illiterate) * able to attend all scheduled visits and to comply with all trial procedures exclusion criteria: * participation in another clinical trial in the 4 weeks preceding the trial vaccination * planned participation in another clinical trial during the present trial period * congenital or acquired immunodeficiency, immunosuppressive therapy such as long-term (for more than 2 weeks) systemic corticosteroid therapy within the preceding 3 months * known systemic hypersensitivity to any of the vaccine components or history of a life-threatening reaction to a vaccine containing the same substances * chronic illness at a stage that could interfere with trial conduct or completion * blood or blood-derived products received in the last 3 months * any vaccination in the 4 weeks preceding the trial vaccination * vaccination planned in the 4 weeks following the trial vaccination * febrile (temperature ≥ 38.0°c) or acute illness on the day of inclusion * history of documented diphtheria, tetanus, pertussis, haemophilus influenzae type b, hepatitis b or poliomyelitis infection(s) (confirmed either clinically, serologically, or microbiologically) * vaccination with a vaccine containing diphtheria, tetanus, pertussis, haemophilus influenzae type b, hepatitis b, or poliovirus 3 types antigen since the end of the primary series * thrombocytopenia or a bleeding disorder contraindicating intramuscular (im) vaccination * serious adverse event related to any vaccination in the al203 study.

Keywords: diphtheria tetanus pertussis hepatitis b hansenula (hb) haemophilus influenzae type b
feasibility study of mixed reality exergame on performance and cortical outcomes

Conditions: Executive Dysfunction; Mild Cognitive Impairment (MCI)

Summary: the executive dysfunctions are a problem in individuals with mci which predict conversion to dementia and is positively related to physical activity level. previous studies found that exercise can prevent executive and physical dysfunctions for people with mci. however, the motivation is a critical factor in supporting a sustainable exercise. exergame is combination of exercise and video game. enjoyment during playing an exergame can support the exercise motivation. therefore, we will explore the feasibility of using mr exergame in people with mci.


Eligibility criteria:
inclusion criteria * healthy group: 1) moca score \> 24; 2) independent walking without using gait aids; 3) no diagnosis of the dementia by clinician. * mci group: 1) moca score between 16 to 24; 2) independent walking without using gait aids. exclusion criteria: * uncontrolled high blood pressure (more than 140/90 mmhg) * hemodialysis * have clinical diagnosis of the disease or symptoms that could influence the performance assessments such as arthritis or severe hand pain which reports by participants and the testing by physiotherapist before testing. * history of neurological disorder, such as stroke or other neurodegenerative disorder * taking medicine which affected to functional movement. * unable to follow study protocol. * uncorrected visual or hearing impairment. * positive screening for contraindication of tms which will be confirmed by tms screening questionnaire such as uncontrolled seizures.

Keywords: feasibility study mixed reality mild cognitive impairment executive dysfunction
ivermectin nasal spray for covid19 patients

Conditions: Covid19

Summary: the global escalation of covid19 pandemic has put the health care system under pressure with urgent need for treatment. in the absence of vaccine and approved drug against sars-cov2 over the past 6 months, the health authorities were obliged to re-purpose existing drugs to fight this pandemic.

ivermectin is a well-known fda-approved pan antiparasitic drug with high safety profile and potential therapeutic effects against covid 19. it has been previously investigated as an antiviral agent. it showed 5000 fold reduction of sars cov 2 viral rna in-vitro studies. however, some researchers questioned its efficacy in the oral form as very high doses will be required to achieve a proper tissue concentration and viricidal effect in the respiratory system. our hypothesis is that, since covid-19 has shown to be particularly damaging to the respiratory system, using inhaled forms of ivermectin will deliver the drug directly to the infection site and make it a treatment option.

Eligibility criteria:
inclusion criteria: * mild to moderate severity who are confirmed to be positive for sars cov 2. exclusion criteria: * patients with severe form of covid-19 or those who are on ventilatory support or those with cytokine storm

Keywords: covid19
biological aspects of depression and antidepressant drugs

Conditions: Depression

Summary: this study will be measuring changes in depressive symptoms over a 7 week time period. double-blind placebo controlled trial using the pharmacologic agents paroxetine or desipramine.


Eligibility criteria:
* diagnosis of major depressive disorder ham-d score \> 18 * english speaking with ability to read and sign an informed consent

Keywords: depression
open-label study with bosentan in interstitial lung disease

Conditions: Interstitial Lung Disease; Scleroderma

Summary: this study will asses the long term safety and efficacy of oral bosentan to patients suffering from interstitial lung disease.


Eligibility criteria:
inclusion criteria: * to have completed the 12-month treatment period of the ac-052-330/build 2. * women should not be pregnant * women of childbearing potential must have a negative pre-treatment pregnancy test and use a reliable method of contraception * signed informed consent prior to initiation of any study-mandated procedure exclusion criteria: * any major violation of the protocol ac-052-330.

Keywords: interstitial lung disease scleroderma bosentan